FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer

Coverage, in order

1. 6d ago
   FDA Drug Safety / Drugs feed indie

   FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer

   FDA granted accelerated approval to zongertinib, a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.